A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 1, 2004, Pages 229-232

  Seiden, Michael V ^a,b   Muggia, Franco ^c   Astrow, Allan ^d   Matulonis, Ursula ^a   Campos, Susanna ^a   Roche, Maria ^a,b   Sivret, Julia ^a,b   Rusk, Jason ^e   Barrett, Emma ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d ST VINCENT S HOSPITAL   (United States)

^e OSI PHARMACEUTICALS INC   (United States)

Author keywords

Liposomal lurtotecan; Topoisomerase I inhibitors; Topotecan resistant ovarian cancer

Indexed keywords

ANTIINFECTIVE AGENT; CA 125 ANTIGEN; DNA TOPOISOMERASE INHIBITOR; LIPOSOME; LURTOTECAN; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACTEREMIA; BLOOD EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGY; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG EMBOLISM; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 1842425347     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.12.037     Document Type: Article

References (14)

1. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15(6):1997;2183-2193.
2. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19(14):2001;3312-3322.
3. Garcia A.A. Salvage therapy for ovarian cancer. Curr. Oncol. Rep. 1(1):1999;64-70.
4. Fung M.F., Johnston M.E., Eisenhauer E.A., Elit L., Hirte H.W., Rosen B. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - A systematic review of the evidence from randomized trials. Eur. J. Gynaecol. Oncol. 23(2):2002;104-110.
5. Harries M., Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3(9):2002;537-545.
6. Kaye S.B. Chemotherapy for recurrent ovarian cancer. Lancet. 361(9375):2003;2094-2095.
7. Hochster H., Wadler S., Runowicz C., Liebes L., Cohen H., Wallach R.et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. 17(8):1999;2553-2561.
8. Emerson D.L., Bendele R., Brown E., Chiang S., Desjardins J.P., Dihel L.C.et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. 6(7):2000;2903-2912.
9. Colbern G.T., Dykes D.J., Engbers C., Musterer R., Hiller A., Pegg E.et al. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 4(12):1998;3077-3082.
10. Kehrer D.F., Bos A.M., Verweij J., Groen H.J., Loos W.J., Sparreboom A. et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J. Clin. Oncol. 20(5):2002;1222-1231.
11. Eisenhauer E.A., Verweij J., Rothenberg M.L., Demetry G.D., DeVries E.E., Gelman K.A.et al. Phase I evaluation of liposomal topoisomerase I inhibitor, NX 211: administered by three schedules to patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;103a.
12. Rothenberg M.L., Gelmon K.A., Eisenhauer E.A., Hirte H., Vermeulen W., Naujoks R.et al. Phase 1 evaluation of liposomal topoisomerase inhibitor, NX211, given on days 1, 2 and 3 or days 1, 8 every 3 weeks to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 19:2000;198.
13. Emerson D.L., Besterman J.M., Brown H.R., Evans M.G., Leitner P.P., Luzzio M.J.et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res. 55(3):1995;603-609.
14. Calvert A.H., Grimshaw R., Poole C., Dark G., Swnerton K., Gore M.et al. Randomized phase II trial of two intravenous schedules of the liposomal topoisomerae I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA): an NCIC CTG study. Proc. Am. Soc. Clin. Oncol. 21:2002;208a.